Tyrosine Kinase Inhibitors: Arrhythmias and Coagulopathy

Osnat Itzhaki Ben Zadok; Zaza Iakobishvili

doi:10.1007/978-3-030-70998-3_6

Tyrosine Kinase Inhibitors: Arrhythmias and Coagulopathy

Osnat Itzhaki Ben Zadok
, Zaza Iakobishvili

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Ibrutinib, a potent Bruton tyrosine kinase inhibitor, is an effective treatment for hematological malignancies including chronic lymphocytic leukemia, Waldenstrom’s macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and chronic graft versus host disease.

Original language	English
Title of host publication	Atlas of Imaging in Cardio-Oncology
Subtitle of host publication	Case-Based Study Guide
Publisher	Springer International Publishing
Pages	49-50
Number of pages	2
ISBN (Electronic)	9783030709983
ISBN (Print)	9783030709976
DOIs	https://doi.org/10.1007/978-3-030-70998-3_6
State	Published - 1 Jan 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Arrhythmia
Atrial fibrillation or flutter
Cardiomyopathy
Heart failure
Tyrosine kinase inhibitor

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-030-70998-3_6

Cite this

@inbook{0f5151223f8c42399d76dff151d3be62,

title = "Tyrosine Kinase Inhibitors: Arrhythmias and Coagulopathy",

abstract = "Ibrutinib, a potent Bruton tyrosine kinase inhibitor, is an effective treatment for hematological malignancies including chronic lymphocytic leukemia, Waldenstrom{\textquoteright}s macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and chronic graft versus host disease.",

keywords = "Arrhythmia, Atrial fibrillation or flutter, Cardiomyopathy, Heart failure, Tyrosine kinase inhibitor",

author = "Zadok, \{Osnat Itzhaki Ben\} and Zaza Iakobishvili",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2021 R. M. Steingart et al. (eds.).",

year = "2021",

month = jan,

day = "1",

doi = "10.1007/978-3-030-70998-3\_6",

language = "English",

isbn = "9783030709976",

pages = "49--50",

booktitle = "Atlas of Imaging in Cardio-Oncology",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Tyrosine Kinase Inhibitors

T2 - Arrhythmias and Coagulopathy

AU - Zadok, Osnat Itzhaki Ben

AU - Iakobishvili, Zaza

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2021 R. M. Steingart et al. (eds.).

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Ibrutinib, a potent Bruton tyrosine kinase inhibitor, is an effective treatment for hematological malignancies including chronic lymphocytic leukemia, Waldenstrom’s macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and chronic graft versus host disease.

AB - Ibrutinib, a potent Bruton tyrosine kinase inhibitor, is an effective treatment for hematological malignancies including chronic lymphocytic leukemia, Waldenstrom’s macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and chronic graft versus host disease.

KW - Arrhythmia

KW - Atrial fibrillation or flutter

KW - Cardiomyopathy

KW - Heart failure

KW - Tyrosine kinase inhibitor

UR - https://www.scopus.com/pages/publications/85171013061

U2 - 10.1007/978-3-030-70998-3_6

DO - 10.1007/978-3-030-70998-3_6

M3 - Chapter

AN - SCOPUS:85171013061

SN - 9783030709976

SP - 49

EP - 50

BT - Atlas of Imaging in Cardio-Oncology

PB - Springer International Publishing

ER -

Tyrosine Kinase Inhibitors: Arrhythmias and Coagulopathy

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this